The impact of thyroid disease on the regulation, expression, and function of ABCB1 (MDR1/P glycoprotein) and consequences for the disposition of digoxin

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 5, 2010, Pages 685-694

  Burk, O ^a,b   Brenner, S S ^a,b   Hofmann, U ^a,b   Tegude, H ^a,b   Igel, S ^a,b   Schwab, M ^a,b,c   Eichelbaum, M ^a,b   Alscher, M D ^b,d  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; DIGOXIN; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE; THYROID HORMONE RECEPTOR; ABCB1 PROTEIN, HUMAN; CARDIOTONIC AGENT; MULTIDRUG RESISTANCE PROTEIN; THYROID HORMONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; HYPERTHYROIDISM; HYPOTHYROIDISM; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CLEARANCE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THYROID FUNCTION; CACO 2 CELL LINE; ENHANCER REGION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; CACO-2 CELLS; CARDIOTONIC AGENTS; DIGOXIN; ENHANCER ELEMENTS, GENETIC; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; RHODAMINES; RNA, MESSENGER; THYROID HORMONES; TRANSFECTION; YOUNG ADULT; P-GLYCOPROTEINS;

EID: 77958514010     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.176     Document Type: Article

References (32)

1. O'Connor, P. & Feely, J. Clinical pharmacokinetics and endocrine disorders. Therapeutic implications. Clin. Pharmacokinet. 13, 345-364 (1987).
2. Eichelbaum, M., Bodem, G., Gugler, R., Schneider-Deters, D. & Dengler, H.J. Infuence of thyroid status on plasma half-life of antipyrine in man. N. Engl. J. Med. 290, 1040-1042 (1974).
3. Shenfeld, G.M., Thompson, J. & Horn, D.B. Plasma and urinary digoxin in thyroid dysfunction. Eur. J. Clin. Pharmacol. 12, 437-443 (1977).
4. Frye, R.L. & Braunwald, E. Studies on digitalis. III. The infuence of triiodothyronine on digitalis requirements. Circulation 23, 376-382 (1961).
5. Doherty, J.E. & Perkins, W.H. Digoxin metabolism in hypo-and hyperthyroidism. Studies with tritiated digoxin in thyroid disease. Ann. Intern. Med. 64, 489-507 (1966).
6. Bradley, S.E., Stéphan, F., Coelho, J.B. & Réville, P. The thyroid and the kidney. Kidney Int. 6, 346-365 (1974).
7. Greiner, B. et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104, 147-153 (1999).
8. Funakoshi, S., Murakami, T., Yumoto, R., Kiribayashi, Y. & Takano, M. Role of P-glycoprotein in pharmacokinetics and drug interactions of digoxin and β-methyldigoxin in rats. J. Pharm. Sci. 92, 1455-1463 (2003).
9. Tsuruoka, S., Sugimoto, K.I., Fujimura, A., Imai, M., Asano, Y. & Muto, S. P-glycoprotein-mediated drug secretion in mouse proximal tubule perfused in vitro. J. Am. Soc. Nephrol. 12, 177-181 (2001).
10. Drescher, S., Glaeser, H., Mürdter, T., Hitzl, M., Eichelbaum, M. & Fromm, M.F. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin. Pharmacol. Ther. 73, 223-231 (2003).
11. Fromm, M.F., Kim, R.B., Stein, C.M., Wilkinson, G.R. & Roden, D.M. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [see comments]. Circulation 99, 552-557 (1999).
12. Mitin, T., Von Moltke, L.L., Court, M.H. & Greenblatt, D.J. Levothyroxine up-regulates P-glycoprotein independent of the pregnane X receptor. Drug Metab. Dispos. 32, 779-782 (2004).
13. Siegmund, W. et al. Efect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition. Clin. Pharmacol. Ther. 72, 256-264 (2002).
14. Geick, A., Eichelbaum, M. & Burk, O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276, 14581-14587 (2001).
15. Burk, O., Arnold, K.A., Geick, A., Tegude, H. & Eichelbaum, M. A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression. Biol. Chem. 386, 503-513 (2005).
16. Croxson, M.S. & Ibbertson, H.K. Serum digoxin in patients with thyroid disease. Br. Med. J. 3, 566-568 (1975).
17. Halkin, H., Sheiner, L.B., Peck, C.C. & Melmon, K.L. Determinants of the renal clearance of digoxin. Clin. Pharmacol. Ther. 17, 385-394 (1975).
18. Eichelbaum, M. Drug metabolism in thyroid disease. Clin. Pharmacokinet. 1, 339-350 (1976).
19. Ford, R.V., Owens, J.C., Curd, G.W. Jr, Moyer, J.H. & Spurr, C.L. Kidney function in various thyroid states. J. Clin. Endocrinol. Metab. 21, 548-553 (1961).
20. Davies, C.E., Mackinnon, J. & Platts, M.M. Renal circulation and cardiac output in low-output heart failure and in myxoedema. Br. Med. J. 2, 595-597 (1952).
21. Hlad, C.J. Jr & Bricker, N.S. Renal function and I131 clearance in hyperthyroidism and myxedema. J. Clin. Endocrinol. Metab. 14, 1539-1550 (1954).
22. van Hoek, I. & Daminet, S. Interactions between thyroid and kidney function in pathological conditions of these organ systems: a review. Gen. Comp. Endocrinol. 160, 205-215 (2009).
23. Ernest, S., Rajaraman, S., Megyesi, J. & Bello-Reuss, E.N. Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney. Nephron 77, 284-289 (1997).
24. Gilfrich, H.J., Bodem, G. & Chidsey, C.A. [Pharmacokinetics of digoxin following acute and chronic administration]. Verh. Dtsch. Ges. Inn. Med. 79, 1039-1042 (1973).
25. Watters, K. & Tomkin, G.H. Letter: Serum digoxin in patients with thyroid disease. Br. Med. J. 4, 102 (1975).
26. Hufman, D.H., Klaassen, C.D. & Hartman, C.R. Digoxin in hyperthyroidism. Clin. Pharmacol. Ther. 22, 533-538 (1977).
27. Lawrence, J.R. et al. Digoxin kinetics in patients with thyroid dysfunction. Clin. Pharmacol. Ther. 22, 7-13 (1977).
28. Kurose, K., Saeki, M., Tohkin, M. & Hasegawa, R. Thyroid hormone receptor mediates human MDR1 gene expression-Identifcation of the response region essential for gene expression. Arch. Biochem. Biophys. 474, 82-90 (2008).
29. Koenig, R.J. Thyroid hormone receptor coactivators and corepressors. Thyroid 8, 703-713 (1998).
30. Becquemont, L. et al. Efects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans. Clin. Pharmacol. Ther. 79, 449-460 (2006).
31. Hitzl, M. et al. The C3435T mutation in the human MDR1 gene is associated with altered efux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 11, 293-298 (2001).
32. Burk, O. et al. Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J. Biol. Chem. 277, 24280-24288 (2002).